Trimetazidine acts as an effective adjunct to conventional treatments, improving symptoms and cardiac function in heart failure by modulating myocardial metabolism.
Does trimetazidine improve cardiac function and symptoms in patients with heart failure?
Trimetazidine serves as a promising adjunctive metabolic therapy in heart failure that improves ejection fraction and symptoms, though large-scale, long-term randomized trials are needed to confirm clinical benefits and safety.
Heart failure is a systemic syndrome caused by multiple pathological factors. Current treatments do not have satisfactory outcomes. Several basic studies have revealed the protective effect of trimetazidine on the heart, not only by metabolism modulation but also by relieving myocardial apoptosis, fibrosis, autophagy, and inflammation. Clinical studies have consistently indicated that trimetazidine acts as an adjunct to conventional treatments and improves the symptoms of heart failure. This review summarizes the basic pathological changes in the myocardium, with an emphasis on the alteration of cardiac metabolism in the development of heart failure. The clinical application of trimetazidine in heart failure and the mechanism of its protective effects on the myocardium are carefully discussed, as well as its main adverse effects. The intention of this review is to highlight this treatment as an effective alternative against heart failure and provide additional perspectives for future studies.
Shu et al. (Tue,) conducted a review in Heart failure. Trimetazidine was evaluated. Trimetazidine acts as an effective adjunct to conventional treatments, improving symptoms and cardiac function in heart failure by modulating myocardial metabolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: